Lithium’s effects on serum neurofilament light in Parkinson’s disease: A post hoc analysis
Open Access
- 14 March 2026
- journal article
- Published by Elsevier in IBRO Neuroscience Reports
- Vol. 20, 506-511
Abstract
No abstract availableKeywords
Funding Information
- National Center for Advancing Translational Sciences (UL1TR001412)
- National Institutes of Health
- Cure Parkinson's Trust
This publication has 41 references indexed in Scilit:
- Plasma NfL, GFAP, amyloid, and p-tau species as Prognostic biomarkers in Parkinson’s diseaseJournal of Neurology, 2024
- Lithium’s effects on therapeutic targets and MRI biomarkers in Parkinson’s disease: A pilot clinical trialIBRO Neuroscience Reports, 2023
- Thalamic Dorsomedial Nucleus Free Water Correlates with Cognitive Decline in Parkinson's DiseaseMovement Disorders, 2021
- Validation of Serum Neurofilament Light Chain as a Biomarker of Parkinson's Disease ProgressionMovement Disorders, 2020
- Interactions of pathological proteins in neurodegenerative diseasesActa Neuropathologica, 2017
- Low-dose lithium adjunct therapy associated with reduced off-time in Parkinson's disease: A case seriesJournal of the Neurological Sciences, 2016
- Lithium prevents parkinsonian behavioral and striatal phenotypes in an aged parkin mutant transgenic mouse modelBrain Research, 2014
- Lithium protects against oxidative stress‐mediated cell death in α‐synuclein‐overexpressing in vitro and in vivo models of Parkinson's diseaseJournal of Neuroscience Research, 2011
- Pooled Analysis of Tobacco Use and Risk of Parkinson DiseaseArchives of Neurology, 2007
- Dietary orotic acid, a new selective growth stimulus for carcinogen altered hepatocytes in rat☆Cancer Letters, 1982